Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +2.55%41 Days Payable is 30.96 as of Jun. 2026, which is 38% below its 10-year median of 50.32. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, Interpace Biosciences ranks worse than 77.78% on this metric.
Interpace Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Interpace Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a Days Payable of 30.96 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Interpace Biosciences and its competitors. This is 38% below median its historical median of 50.32. Over the past decade, Interpace Biosciences' Days Payable has ranged from 25.95 to 106.79. According to the industry distribution chart, Interpace Biosciences ranks #147 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 77.8%.
Is Interpace Biosciences' Days Payable too high?
Interpace Biosciences' current Days Payable of 30.96 is 38% below median its 10-year median of 50.32. Over the past 10 years, this metric has ranged from a low of 25.95 to a high of 106.79. The Medical Diagnostics & Research industry median Days Payable is 64.92. Interpace Biosciences' value of 30.96 is 52.3% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #147 out of 189 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Days Payable compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #147 out of 189 companies for Days Payable. This places Interpace Biosciences in the lower half of its industry. The industry median Days Payable is 64.92. Interpace Biosciences' value of 30.96 is 52.3% below this benchmark. Historically, Interpace Biosciences' own Days Payable has ranged from 25.95 to 106.79 over the past decade. While the company's 10-year median is 50.32 vs. the industry median of 64.92, Interpace Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.92, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Days Payable of 30.96 is 52.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Days Payable is 30.96, which is 38% below median its own 10-year median of 50.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current Days Payable is 30.96, which is 38% below median its 10-year median of 50.32 and 52.3% below the Medical Diagnostics & Research industry median of 64.92. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Days Payable is 30.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
Days Payable: 30.96 (38% below median its 10-year median of 50.32)
GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
Industry Position: 52.3% below the Medical Diagnostics & Research median (#147 of 189)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
